CTKB Earnings Date: Nov 4, 2026 (Estimated) — Cytek Biosciences, Inc.
NASDAQ · Healthcare · Medical Devices
Updated
When is CTKB's next earnings date?
Cytek Biosciences, Inc. (CTKB) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.08 on revenue of $53.0M.
How did CTKB do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Cytek Biosciences, Inc. posted EPS of -$0.09 versus the -$0.09 estimate, a beat of 350.0%. Revenue was $48.1M against a $47.3M estimate. The stock's 1-day post-earnings move was -0.5%.
How much does CTKB stock move after earnings?
CTKB beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.9% (up or down) in the day after earnings.
About Cytek Biosciences, Inc.
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially adopted the name Cytek Biosciences, Inc. in August 2015. Its corporate headquarters are situated in Fremont, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.09 | -0.09 | -350.00% | $48.1M | ✅ Beat | -0.48% | +14.35% | +12.44% |
| 2026-05-07 | Q1 2026 | -0.09 | -0.15 | -66.67% | $44.1M | ❌ Miss | -6.30% | -31.81% | -17.89% |
| 2026-02-26 | Q4 2025 | -0.01 | -0.34 | -3300.00% | $62.1M | ❌ Miss | +1.82% | -0.45% | -1.82% |
| 2025-11-05 | Q3 2025 | -0.01 | -0.04 | -300.00% | $52.3M | ❌ Miss | +13.22% | +19.95% | +24.44% |
| 2025-08-06 | Q2 2025 | -0.04 | -0.04 | +0.00% | $45.6M | ➖ Inline | +5.66% | +7.20% | +3.34% |
| 2025-02-27 | Q4 2024 | 0.10 | 0.07 | -30.00% | $57.5M | ❌ Miss | -6.65% | -7.28% | -16.84% |
| 2024-11-05 | Q3 2024 | -0.01 | 0.01 | +200.00% | $51.5M | ✅ Beat | +36.03% | +29.41% | +20.22% |
| 2024-08-06 | Q2 2024 | -0.03 | -0.08 | -166.67% | $46.6M | ❌ Miss | -9.43% | -4.80% | -3.20% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $78.9M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Service | 58.7% | $46.3M | +5.2% | — | $42.4M | $44.0M | $43.1M |
| Product | 41.3% | $32.6M | +3.6% | $79.6M | $28.1M | $31.4M | $38.1M |
By region
Q2 FY26 · $48.1M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 58.6% | $28.2M | +18.1% | $46.9M | $18.5M | $23.9M | $27.2M |
| EMEA | 23.5% | $11.3M | -8.2% | $30.0M | $11.6M | $12.3M | $12.4M |
| Asia Pacific | 16.4% | $7.9M | +0.6% | $20.5M | $8.9M | $7.9M | $11.1M |
| Other | 1.5% | $701K | -54.2% | $6.7M | $2.5M | $1.5M | $1.6M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.